NewAmsterdam Pharma (NASDAQ:NAMS) Upgraded at BMO Capital Markets

BMO Capital Markets upgraded shares of NewAmsterdam Pharma (NASDAQ:NAMS) to a strong-buy rating in a report published on Monday morning,Zacks.com reports.

NAMS has been the topic of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NewAmsterdam Pharma in a report on Friday, July 17th. Jefferies Financial Group reiterated a “buy” rating and issued a $45.00 price target on shares of NewAmsterdam Pharma in a research note on Monday. Wall Street Zen raised shares of NewAmsterdam Pharma from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Finally, Royal Bank Of Canada increased their price objective on shares of NewAmsterdam Pharma from $47.00 to $51.00 and gave the company an “outperform” rating in a research report on Tuesday, June 30th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.42.

NewAmsterdam Pharma Price Performance

Shares of NASDAQ:NAMS opened at $31.70 on Monday. The company has a market cap of $3.71 billion, a P/E ratio of -17.71 and a beta of 0.08. NewAmsterdam Pharma has a 1 year low of $21.14 and a 1 year high of $42.21. The stock’s fifty day moving average price is $33.05 and its 200-day moving average price is $32.92.

NewAmsterdam Pharma (NASDAQ:NAMS) last released its quarterly earnings data on Tuesday, March 31st. The company reported ($0.40) EPS for the quarter. NewAmsterdam Pharma had a negative return on equity of 26.49% and a negative net margin of 943.23%.The business had revenue of $3.04 million during the quarter. On average, sell-side analysts anticipate that NewAmsterdam Pharma will post -1.78 earnings per share for the current year.

Insider Activity

In other NewAmsterdam Pharma news, CAO Louise Frederika Kooij sold 40,000 shares of the business’s stock in a transaction dated Monday, June 22nd. The stock was sold at an average price of $30.20, for a total transaction of $1,208,000.00. Following the completion of the sale, the chief accounting officer directly owned 24,353 shares in the company, valued at $735,460.60. The trade was a 62.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 12.74% of the stock is currently owned by corporate insiders.

Institutional Trading of NewAmsterdam Pharma

Several large investors have recently added to or reduced their stakes in NAMS. Swedbank AB bought a new stake in NewAmsterdam Pharma during the fourth quarter valued at about $3,189,000. Legato Capital Management LLC raised its stake in shares of NewAmsterdam Pharma by 258.7% in the fourth quarter. Legato Capital Management LLC now owns 83,833 shares of the company’s stock worth $2,941,000 after buying an additional 60,463 shares during the period. UBS Group AG raised its stake in shares of NewAmsterdam Pharma by 17.0% in the fourth quarter. UBS Group AG now owns 899,442 shares of the company’s stock worth $31,552,000 after buying an additional 130,922 shares during the period. JTC Employer Solutions Trustee Ltd bought a new position in shares of NewAmsterdam Pharma in the fourth quarter worth about $2,649,000. Finally, Aberdeen Group plc lifted its position in shares of NewAmsterdam Pharma by 10.2% during the 4th quarter. Aberdeen Group plc now owns 729,484 shares of the company’s stock valued at $25,590,000 after buying an additional 67,538 shares in the last quarter. 89.89% of the stock is currently owned by institutional investors.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.